Home Newsfeeds Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

5 Most Expensive Tech Stocks You Should Worry About

By Lisa Levin

January 17, 8:18 AM

The most overbought stocks in the information technology sector presents an opportunity to go short on these overvalued companies.

API

Crypto Leaders React To Historic SEC Bitcoin ETF Approval: ‘Huge Inflection Point For Digital Assets’

By Murtuza Merchant

January 10, 7:23 PM

The crypto industry on Wednesday hailed the SEC's decision to approve all spot Bitcoin (CRYPTO: BTC) exchange-traded fund applications, assert

$USDT

Roku Investor Sentiment Decidedly Negative Into Earnings, Says Analyst

By Shivani Kumaresan

April 22, 2:01 PM

J.P. Morgan analyst Cory A Carpenter reiterated an Overweight rating on the shares of Roku. Roku is slated to report first-quarter FY24 earnings on Thursday, April 24.

ROKU

Analyst Ratings

Analyst Ratings For Vertiv Hldgs

By Benzinga Insights

May 15, 9:00 AM

Vertiv Hldgs (NYSE:VRT) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from…

VRT

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Related Posts

5 Most Expensive Tech Stocks You Should Worry About

Crypto Leaders React To Historic SEC Bitcoin ETF Approval: ‘Huge Inflection Point For Digital Assets’

Roku Investor Sentiment Decidedly Negative Into Earnings, Says Analyst

Analyst Ratings For Vertiv Hldgs